{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Percentage of participants with severe complications defined at ICU admission and death, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.","groups":[{"description":"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.\n\nAfter collection, participants will receive dexamethasone x 4 days every 14 days.\n\nTransplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.\n\nOnce recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.\n\nConsolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)\n\nMaintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles.\n\ndexamethasone: Given PO\n\ncisplatin: Given IV\n\ndoxorubicin: Given IV\n\ncyclophosphamide: Given IV or PO\n\netoposide: Given IV\n\nbortezomib: Given IV\n\nthalidomide: Given PO\n\nmelphalan: Given IV\n\nautologous stem cell transplant","id":"OG000","title":"Autologous Stem Cell Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who have had at least one day of protocol treatment","reportingStatus":"POSTED","timeFrame":"From the start of DPACE for all participants who have had at least one day of protocol treatment. Up to 6 years.","title":"Percentage of Participants With Serious Treatment-Related Complications","type":"PRIMARY","unitOfMeasure":"Participants"}